6. PROCEPT BioRobotics Corporation (NASDAQ:PRCT)
With a street-high upside potential of 109.4%, PROCEPT BioRobotics Corporation (NASDAQ:PRCT) ranks among the 10 best robotics stocks to buy under $30.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) has had a productive stretch heading into mid-2026, with two developments that together strengthen both the clinical and commercial case for Aquablation therapy.
The first arrived on March 23, 2026, when the European Association of Urology granted Aquablation one of the more consequential votes of confidence a surgical therapy can earn in global urology, elevating it to a strong recommendation for addressing male lower urinary tract symptoms stemming from benign prostatic hyperplasia. The revised guidelines put Aquablation forward as a preferred surgical option over TURP for men dealing with moderate-to-severe BPH symptoms, with considerable emphasis placed on its capacity to maintain ejaculatory function and broader quality of life.
The upgrade did not arrive without evidence behind it.
The recommendation draws on multiple studies, including the WATER randomized trial pitting Aquablation directly against TURP, WATER II establishing durable symptom relief over time, and emerging WATER III data covering larger prostate glands and head-to-head comparisons with laser-based procedures. Management was measured in its response, calling the upgrade an important step in expanding clinical credibility.
The second development came eleven days before that, on March 12, 2026, when PROCEPT BioRobotics Corporation (NASDAQ:PRCT) took its HYDROS Robotic System international. Built specifically for Aquablation therapy, HYDROS combines real-time ultrasound imaging with algorithmic treatment planning to make procedures more targeted and tailored to each patient, and it is designed to work across a much wider range of clinical environments than what came before it.
PROCEPT BioRobotics Corporation (NASDAQ:PRCT)’s driving intention is to make the therapy reproducible and scalable, without eroding what has defined Aquablation’s track record: sustained symptom control and the safeguarding of sexual and urinary function.
Procept BioRobotics Corporation (NASDAQ:PRCT) is a commercial-stage surgical robotics company that develops transformative solutions in urology in the U.S. and internationally.
While we acknowledge the potential of PRCT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PRCT and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see the 5 Best Robotics Stocks to Buy Under $30.
Disclosure: None. Follow Insider Monkey on Google News.
